Structure and Functions of T-cell Immunoglobulin-domain and Mucin- domain Protein 3 in Cancer / Xinjie Lu
Background: T-cell immunoglobulin (Ig)-domain and mucin-domain (TIM) proteins represent a family of receptors expressed on T-cells that play essential cellular immunity roles. The TIM proteins span across the membrane belonging to type I transmembrane proteins. The N terminus contains an Ig-like V-type domain and a Ser/Thr-rich mucin stalk as a co-inhibitory receptor. The C-terminal tail oriented toward the cytosol predominantly mediates intracellular signaling. Methods: This review discusses the structural features and functions of TIM-3, specifically on its role in mediating immune responses in different cell types and the rationale for TIM-3-targeted cancer immunotherapy. Results: TIM-3 has gained significant importance to be a potential biomarker in cancer immunotherapy. It has been shown that blockade with checkpoint inhibitors promotes anti-tumor immunity and inhibits tumor growth in several preclinical tumor models. Conclusion: TIM-3 is an immune regulating molecule expressed on several cell types, including IFNγ-producing T-cells, FoxP3+ Treg cells, and innate immune cells. The roles of TIM-3 in immunosuppression support its merit as a target for cancer immunotherapy.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
---|---|
Enthalten in: |
Current medicinal chemistry - 29(2022), 11, Seite 15 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Lu, Xinjie [VerfasserIn] |
---|
Links: |
FID Access [lizenzpflichtig] |
---|
Umfang: |
1 Online-Ressource (15 p) |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
KFL011164573 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | KFL011164573 | ||
003 | DE-627 | ||
005 | 20231128150401.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230613s2022 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)KFL011164573 | ||
035 | |a (KFL)prod_DARH_.0ABFA5FCE01ABA70F1EAFF962E46C9379D0E8C08 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
084 | |a PHARM |q DE-84 |2 fid | ||
100 | 1 | |a Lu, Xinjie |e verfasserin |4 aut | |
245 | 1 | 0 | |a Structure and Functions of T-cell Immunoglobulin-domain and Mucin- domain Protein 3 in Cancer |c Xinjie Lu |
264 | 1 | |c 2022 | |
300 | |a 1 Online-Ressource (15 p) | ||
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Background: T-cell immunoglobulin (Ig)-domain and mucin-domain (TIM) proteins represent a family of receptors expressed on T-cells that play essential cellular immunity roles. The TIM proteins span across the membrane belonging to type I transmembrane proteins. The N terminus contains an Ig-like V-type domain and a Ser/Thr-rich mucin stalk as a co-inhibitory receptor. The C-terminal tail oriented toward the cytosol predominantly mediates intracellular signaling. Methods: This review discusses the structural features and functions of TIM-3, specifically on its role in mediating immune responses in different cell types and the rationale for TIM-3-targeted cancer immunotherapy. Results: TIM-3 has gained significant importance to be a potential biomarker in cancer immunotherapy. It has been shown that blockade with checkpoint inhibitors promotes anti-tumor immunity and inhibits tumor growth in several preclinical tumor models. Conclusion: TIM-3 is an immune regulating molecule expressed on several cell types, including IFNγ-producing T-cells, FoxP3+ Treg cells, and innate immune cells. The roles of TIM-3 in immunosuppression support its merit as a target for cancer immunotherapy | ||
773 | 0 | 8 | |i Enthalten in |t Current medicinal chemistry |d Hilversum [u.a.] : Bentham Science Publ., 1996 |g 29(2022), 11, Seite 15 |h Online-Ressource |w (DE-627)KFL000006319 |w (DE-600)2034240-8 |w (DE-576)273880209 |x 1875-533X |7 nnns |
773 | 1 | 8 | |g volume:29 |g year:2022 |g number:11 |g pages:15 |
856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=0929-8673&volume=29&issue=11&spage=1851 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
912 | |a ZDB-1-BEJ | ||
912 | |a GBV_KFL | ||
912 | |a FID-PHARM | ||
935 | |i IMPORT_0628_prod_DARH_03 | ||
951 | |a AR | ||
952 | |d 29 |j 2022 |e 11 |h 15 |